Find disease awareness content and relevant supporting materials
Durability of treatment effects of the Sleep Position Trainer versus oral appliance therapy in positional OSA: 12-month follow-up of a randomized controlled trial
Purpose: The Sleep Position Trainer (SPT) is a new option for treating patients with positional obstructive sleep apnea (POSA).
Phase III analysis of Xtampza ER (oxycodone extended-release capsules) for chronic pain published in Current Medical Research and Opinion- Collegium Pharmaceutical
Collegium Pharmaceutical has announced the publication of an analysis of the duration of effect of Xtampza ER (oxycodone extended-release capsules)...
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation.
New data demonstrate clinical safety, benefit and durability of Nexviazyme (avalglucosidase alfa) across a wide-range of Pompe disease patient groups
New data suggest treatment with Nexviazyme (avalglucosidase alfa) meaningfully improved ptosis, or drooping eyelid, in pediatric patients with infantile-onset Pompe disease (IOPD) over nearly three years
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
FDA accepts for priority review application for Augtyro (repotrectinib) for the treatment of patients with NTRK-positive locally advanced or metastatic solid tumors
Bristol Myers Squibb announced that the FDA has accepted the supplemental New Drug Application (sNDA) for Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials
Purpose: To report the durability of voretigene neparvovec-rzyl (VN) adeno-associated viral vector-based gene therapy for RPE65 mutation-associated inherited retinal dystrophy (IRD), including results of a phase 1 follow-on study at year 4 and phase 3 study at year 2.